Transarterial Chemoembolization (TACE)
Treatment for Liver Cancer Due To Alcohol Use
Effectiveness
70%
Safety Score
65%
Clinical Trials
100
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Time to Effect
Clinical benefit seen within weeks to months
Treatment Duration
Repeated every 1-3 months for several cycles
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$45,000
Side Effect Mgmt:$5,000
Total Annual:$50,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.75
Outcome-Based Costs
Cost per Responder
$90,909
Cost per Remission
$250,000
Transarterial Chemoembolization (TACE) Outcomes
for Liver Cancer Due To Alcohol Use
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+55%
Remission Rate
+20%
Common Side Effects
Post-embolization syndrome (fever, pain, nausea)
+70%
Liver function abnormalities
+40%
Fatigue
+35%
Infection
+3%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov